RxDoctor Payments Data

Walid Abboud, MD

Internal Medicine · Cleveland, OHNPI 1245295559

Payments from drug & device makers

$4,513in general payments, 2019–2025

Across 54 payments — averaging $83.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$2K
  • Esperion Therapeutics, Inc.$1K
  • AstraZeneca$807
  • Johnson & Johnson$411
  • Abiomed$53
  • Novartis$24
  • plus $56 from 3 others

What the payments were for

  • Food & beverage$4,513100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,513 in reported general payments places this provider in the 85th percentile of 4,428 internal medicine providers in Ohio.

See all internal medicine providers in Ohio

Medicare billing

Part B allowed, 2024
$393,194
Medicare patients
853
Services billed
3,822

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban287$85,447
RexultiBrexpiprazole28$22,022
CreonLipase/Protease/Amylase24$15,417
ArexvyRsvpref3 Antigen/As01e/Pf44$13,405
Fiasp FlextouchInsulin Aspart (Niacinamide)43$11,734
Lidocaine37$11,010
XareltoRivaroxaban36$10,970
Divalproex Sodium146$9,371
JardianceEmpagliflozin26$9,255
VascepaIcosapent Ethyl24$8,667
JanuviaSitagliptin Phosphate28$8,060
Cyclosporine35$7,348
ZenpepLipase/Protease/Amylase15$6,816
Chlorpromazine Hcl22$5,768
Atorvastatin Calcium357$5,727

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Synjardy Xr, Jentadueto Xr$1,849$19,02561 claims
AbbVieCreon, Alphagan P$17$17,94536 claims
Johnson & JohnsonXarelto$411$10,97036 claims
Novo NordiskFiasp$17$4,08413 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,428 internal medicine providers in Ohio.

Other internal medicine in Cleveland

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →